TY - JOUR
T1 - Biomaterials for CNS disorders
T2 - a review of development from traditional methods to AI-assisted optimization
AU - Haramshahi, Seyed Mohammad Amin
AU - Hamblin, Michael R.
AU - Ravesh, Roya Khosh
AU - Sadr, Hossein
AU - Ahmadirad, Nooshin
AU - Mehrabi, Fatemeh
AU - Taherian, Zahra
AU - Hosseingolipour, Saba
AU - Barzegar, Zeynab
AU - Mehrabi, Soraya
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Treating neurodegenerative and traumatic brain disorders is profoundly challenging due to factors like permanent tissue loss and the restrictive nature of the Blood-Brain Barrier (BBB), which limits drug delivery to the brain. Biomaterials offer a promising therapeutic strategy, serving as scaffolds for tissue regeneration or as platforms for the controlled and sustained release of therapeutic agents. These materials can localize treatment to the site of injury and prevent the rapid clearance of drugs from circulation. However, the development of biomaterials with the precise properties required for these complex applications is often slow and resource-intensive when using traditional trial-and-error methods. Artificial intelligence (AI) is emerging as a paradigm shift to overcome this limitation, poised to revolutionize the field by enabling the intelligent design, virtual screening, and rapid selection of optimal biomaterials. By analyzing vast datasets of material and biological properties, AI can accelerate the development of more effective and personalized treatments. This review examines innovative biomaterials and their applications in conditions such as ischemic stroke, spinal cord injury, and neurodegenerative diseases. A central focus is placed on how the integration of AI is accelerating the discovery of novel treatments, paving the way for the future of therapy for neurological disorders.
AB - Treating neurodegenerative and traumatic brain disorders is profoundly challenging due to factors like permanent tissue loss and the restrictive nature of the Blood-Brain Barrier (BBB), which limits drug delivery to the brain. Biomaterials offer a promising therapeutic strategy, serving as scaffolds for tissue regeneration or as platforms for the controlled and sustained release of therapeutic agents. These materials can localize treatment to the site of injury and prevent the rapid clearance of drugs from circulation. However, the development of biomaterials with the precise properties required for these complex applications is often slow and resource-intensive when using traditional trial-and-error methods. Artificial intelligence (AI) is emerging as a paradigm shift to overcome this limitation, poised to revolutionize the field by enabling the intelligent design, virtual screening, and rapid selection of optimal biomaterials. By analyzing vast datasets of material and biological properties, AI can accelerate the development of more effective and personalized treatments. This review examines innovative biomaterials and their applications in conditions such as ischemic stroke, spinal cord injury, and neurodegenerative diseases. A central focus is placed on how the integration of AI is accelerating the discovery of novel treatments, paving the way for the future of therapy for neurological disorders.
UR - https://www.scopus.com/pages/publications/105018647405
U2 - 10.1007/s10856-025-06947-7
DO - 10.1007/s10856-025-06947-7
M3 - Review article
C2 - 41085749
AN - SCOPUS:105018647405
SN - 0957-4530
VL - 36
JO - Journal of Materials Science: Materials in Medicine
JF - Journal of Materials Science: Materials in Medicine
IS - 1
M1 - 85
ER -
